Found: 7
Select item for more details and to access through your institution.
Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin.
- Published in:
- Cell Death & Disease, 2021, v. 12, n. 12, p. 1, doi. 10.1038/s41419-021-04375-3
- By:
- Publication type:
- Article
The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study.
- Published in:
- Clinical & Translational Immunology, 2021, v. 10, n. 3, p. 1, doi. 10.1002/cti2.1257
- By:
- Publication type:
- Article
Time-varying pattern of recurrence risk for localized melanoma in China.
- Published in:
- World Journal of Surgical Oncology, 2020, v. 18, n. 1, p. 1, doi. 10.1186/s12957-019-1775-5
- By:
- Publication type:
- Article
Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis.
- Published in:
- Cancer Management & Research, 2018, v. 10, p. 2141, doi. 10.2147/CMAR.S164535
- By:
- Publication type:
- Article
A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series.
- Published in:
- Cancer Immunology, Immunotherapy, 2017, v. 66, n. 9, p. 1153, doi. 10.1007/s00262-017-1989-8
- By:
- Publication type:
- Article
The clinical significance of transforming acidic coiled-coil protein 3 expression in non-small cell lung cancer.
- Published in:
- Oncology Reports, 2016, v. 35, n. 1, p. 436, doi. 10.3892/or.2015.4373
- By:
- Publication type:
- Article